That's because FDA flexibility can mean approval for drugs that are too dangerous or simply do not work. Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

That’s because FDA flexibility can mean approval for drugs that are too dangerous or simply do not work. Skorney cited a drug ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

COURT: N.D. Cal. TRACK DOCKET: No. 3:24-cv-07786 (Bloomberg Law subscription) Pfizer Inc. and its subsidiary Global Blood Therapeutics Inc. should have known that their now-recalled treatment for ...